Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Disc Medicine, Inc. - Common Stock (NQ: IRON ) 45.07 +0.72 (+1.62%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Disc Medicine, Inc. - Common Stock < Previous 1 2 Next > Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2023 May 17, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023 April 28, 2023 Via Benzinga Expert Ratings for Disc Medicine April 26, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023 April 21, 2023 Via Benzinga Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday March 31, 2023 U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording losses in today’s session. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023 April 20, 2023 Via Benzinga Why Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket March 24, 2023 Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 58.7% to $0.2250 in pre-market trading after gaining more than 17% on Thursday. Bird announced plans to expand across Greater Toronto area this... Via Benzinga Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 31, 2023 Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023 March 23, 2023 Via Benzinga Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement March 18, 2023 Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had... Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 February 28, 2023 Via Benzinga $2M Bet On PayPal? Check Out These 4 Stocks Insiders Are Buying February 21, 2023 Although US stocks closed mixed on Friday, there were a few notable insider trades. Via Benzinga Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million January 21, 2023 Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 January 04, 2023 Via Benzinga Stocks Stumbling Out Of 2023's Gate January 03, 2023 Stocks were unable to fulfill premarket gains, as two familiar foes -- rising rates and high inflation -- dampen investor sentiment to start the new trading year. Via Talk Markets 12 Health Care Stocks Moving In Tuesday's Pre-Market Session January 03, 2023 Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.